In honor of World AIDS Day, Treatment Action Group (TAG) continues to stand with the global harm reduction movement in support of evidence based, live saving interventions for people who use drugs, including syringe service programs and safer consumption spaces (SCS).
Treatment Action Group (TAG) welcomes the U.S. Department of Health and Human Services (HHS) pursuit of a lawsuit against Gilead Sciences, Inc., the manufacturer of Truvada and Descovy, the only two FDA-approved pills for pre-exposure prophlyaxis (PrEP) to prevent HIV.
Treatment Action Group (TAG) is honored that acclaimed American Artist Glenn Ligon has created and donated a Limited Art Edition entitled Black Rage (back cover) in an edition of 100 prints (and 20 A/Ps) especially for TAG.
On October 25, 2019, eight HIV/AIDS research, policy, and advocacy organizations filed an amicus brief in the U.S. District Court, in San Francisco, CA, in support of the plaintiffs in Staley v. Gilead.
As an organization dedicated to ensuring equitable access to critical health services to individuals and communities affected by HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV), Treatment Action Group (TAG) strongly opposes the proposed changes regarding “public charge,” published in the Federal Register on October 11, 2019 (the proposed rule).
The ACT NOW: END AIDS (ANEA) coalition is seeking proposals for a new small grants program that aims to significantly increase local and state community leadership as part of the new federal Ending the HIV Epidemic (EHE): A Plan for America initiative.
October 21, 2019 – The ACT NOW: END AIDS (ANEA) coalition is seeking proposals for a new small grants program that aims to significantly increase local and state community leadership as part of the new federal Ending the HIV Epidemic…
This is a joint statement from TAG and Health GAP October 16, 2019 – Although Speaker Nancy Pelosi’s bill to increase affordable access to medicines in the U.S., H.R. 3, offers halting, partial steps to reduce drug prices for some…
TAG, AVAC, The Well Project and the Women’s Research Initiative (WRI) co-convened this webinar on Monday, October 7. It was the first in a two-part series, responding to advocates’ desire to better understand the research to date on F/TAF as…
TAG laments that development for the latest oral HIV pre-exposure prophylaxis (PrEP) left out cisgender women and transgender men, but welcomes the accountability provided—albeit belated—by the U.S. Food and Drug Administration (FDA) to rectify this inequity.